Don’t miss out on the next big thing in the life sciences.

Todd Dickinson, President & CEO, Stellaromics

In this Q&A, Dickinson explains why conventional spatial platforms lose critical biological information by cutting tissue too thin, how Stellaromics’ Pyxa® platform preserves native tissue architecture in sections up to 100 microns thick, and what that means for drug discovery, tumor biology, and ultimately patient care. He also speaks candidly about the realities of leading an early-stage tools company in a constrained funding environment, the culture he is building in Boston, and why — despite growing political headwinds facing science — he remains genuinely optimistic about the longer arc of progress.